Immunophenotype, microRNA expression and cytogenetic characterization of acute leukemias of ambiguous lineage

被引：0

作者：

Golchin N. ^{[1
]}

Khodadi E. ^{[1
]}

Yaghooti S.H. ^{[2
]}

Jaseb K. ^{[1
]}

Shahjahani M. ^{[1
]}

Tavakolifar Y. ^{[1
]}

Saki N. ^{[1
]}

机构：

[1] Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz

[2] Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz

来源：

Comparative Clinical Pathology | 2017年 / 26卷 / 2期

关键词：

Acute leukemias of ambiguous lineage; Cytogenetic; Immunophenotype; MicroRNAs;

D O I：

10.1007/s00580-015-2134-8

中图分类号：

学科分类号：

摘要：

Acute leukemias of ambiguous lineage (ALAL) form a group of leukemias presenting the features of both acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML). Based on Immunologic Classification of Leukemia (EGIL), these leukemias are recognized as biphenotype acute leukemia (BAL). According to WHO classification and based on immunophenotypic characteristics, ALAL is further categorized to acute undetermined leukemia (AUL), mixed phenotype acute leukemia (MPAL), and other ambiguous lineage leukemias. Immunophenotype and cytogenetic aspects are important in recognition of these leukemias; however, there is limited data about these leukemias. This has resulted in mistreatment of patients. Thanks to the recent advances and introducing the role of microRNAs in regulation of gene expression, a new avenue has been opened in the field of classification and pathogenesis of ambiguous lineage leukemias. MiRNA-based classification can help define myeloid or lymphoid origin of ambiguous lineage leukemias. Taking immunophenotype, cytogenetic, and miRNA profiles into account collectively, a better recognition of the disease is achieved, which results in accurate diagnosis and effective treatment of patients. In this review, we have discussed ambiguous lineage leukemias with regard to microRNA expression, immunophenotype, and cytogenetic aspects. © 2015, Springer-Verlag London.

引用

页码：261 / 267

页数：6

共 36 条

[1]

Babashah S., Sadeghizadeh M., Rezaie Tavirani M., Farivar S., Soleimani M., Aberrant microRNA expression and its implications in the pathogenesis of leukemias, Cell Oncol, 35, pp. 317-334, (2012)

[2]

Bene Marie C., Billinage, ambiguous lineage or mixed lineage: strange leukemias, Haematologica, 44, pp. 891-893, (2009)

[3]

Bene M.C., Porwit A., Acute leukemias of ambiguous lineage, Semin Diagn Pathol, 29, pp. 12-18, (2012)

[4]

Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., Et al., Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia, 9, pp. 1783-1786, (1995)

[5]

De Leeuw D.C., Ankers W.V.D., Denkers F., De Menezes R.X., Westers T.M., Ossenkoppele G.J., Et al., MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymhoid leukemia, Am Assoc Cancer Res, 19, pp. 2187-2196, (2013)

[6]

Heuser M., Argiropoulos B., Kuchenbauer F., Yung E., Piper J., Fung S., MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML, Blood, 110, pp. 1639-1647, (2007)

[7]

Ichikawa H., Shimizu K., Hayashi Y., Ohki M., An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16

[8]

21) chromosomal translocation, Am Assoc Cancer Res, 11, pp. 2865-2868, (1994)

[9]

Keilholz U., Letsch A., Busse A., Asemissen A.M., Bauer S., Wolfgang Blau I., Et al., A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS, Blood, 113, pp. 6541-6548, (2009)

[10]

← 1 2 3 4 →